Prevention of DNA damage and anticarcinogenic activity of Activia(®) in a preclinical model.

Related Articles

Prevention of DNA damage and anticarcinogenic activity of Activia(®) in a preclinical model.

Genet Mol Res. 2017 Mar 22;16(1):

Authors: Limeiras SM, Ogo FM, Genez LA, Carreira CM, Oliveira EJ, Pessatto LR, Neves SC, Pesarini JR, Schweich LC, Silva RA, Cantero WB, Antoniolli-Silva AC, Oliveira RJ

Abstract
Colorectal cancer is a global public health issue. Studies have pointed to the protective effect of probiotics on colorectal carcinogenesis. Activia(®) is a lacto probiotic product that is widely consumed all over the world and its beneficial properties are related, mainly, to the lineage of traditional yoghurt bacteria combined with a specific bacillus, DanRegularis, which gives the product a proven capacity to intestinal regulation in humans. The aim of this study was to evaluate the antigenotoxic, antimutagenic, and anticarcinogenic proprieties of the Activia product, in response to damage caused by 1,2-dimethylhydrazine (DMH) in Swiss mice. Activia does not have shown antigenotoxic activity. However, the percent of DNA damage reduction, evaluated by the antimutagenicity assay, ranged from 69.23 to 96.15% indicating effective chemopreventive action. Activia reduced up to 79.82% the induction of aberrant crypt foci by DMH. Facing the results, it is inferred that Activia facilitates the weight loss, prevents DNA damage and pre-cancerous lesions in the intestinal mucosa.

PMID: 28340269 [PubMed - indexed for MEDLINE]

http://ift.tt/2qijQrR